Publications dans lesquelles il/elle collabore avec Carlos López López (14)

2023

  1. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  2. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2021

  1. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

  2. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

    Oncologist, Vol. 26, Núm. 11, pp. 941-949

2020

  1. Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas

    Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909

  2. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

    Cancer Medicine, Vol. 9, Núm. 3, pp. 1008-1016

2019

  1. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

    Therapeutic Advances in Endocrinology and Metabolism, Vol. 10

  2. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573

  3. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  4. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46

  5. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 55-63

2017

  1. Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors

    Current Oncology Reports, Vol. 19, Núm. 11

2016

  1. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: Results of a Delphi questionnaire panel from the NETPraxis program

    BMC Cancer, Vol. 16, Núm. 1